Onco Wiki / Indication

Kaposi sarcoma · line 1 · Pegylated liposomal doxorubicin monotherapy (Kaposi sarcoma)

Deterministic view of the source YAML entity. Clinical authority remains with the cited source IDs and reviewer sign-off state.

Knowledge-base record for audit. Provisional clinical content: this is not a prescription. An oncologist must verify original sources, applicability and review status. Full rules and constraints are in the YAML.

Source YAML: complete record

Line of therapy1
Trackstandard
Linked regimenREG-PLD-KAPOSI
IDIND-KAPOSI-1L-VISCERAL-PLD
TypeIndication
Statusreviewed 2026-07-11 | pending_clinical_signoff
DiseasesDIS-KAPOSI
SourcesSRC-NCCN-SKIN-2025 SRC-NIH-AIDS-2024

Notes

STUB -- new TREATMENT-intent Indication for DIS-KAPOSI (v0.3 continuation), covering visceral/extensive disease of ANY epidemiologic form. Introduces new Regimen REG-PLD-KAPOSI (reuses the existing DRUG-PEGYLATED-LIPOSOMAL-DOXORUBICIN entity; dosing transcribed from that entity's pre-existing typical_dosing field, not newly invented -- verified by direct read during independent review). `concurrent_therapy` is deliberately left empty rather than hard-coding REG-HIV-BIKTARVY or REG-SIROLIMUS-KAPOSI-CONVERSION, because this Indication spans ALL epidemiologic forms and only a subset needs concurrent form-specific immune-restoration therapy -- see `rationale` for the form-specific guidance instead. INDEPENDENT REVIEW CORRECTION (2026-07-11): an earlier draft cited SRC-NCCN-SKIN-2025 with position "supports". That source documents only basal-cell/squamous-cell skin cancer (confirmed by direct inspection of its own KB record), not Kaposi sarcoma chemotherapy -- downgraded to "context". SRC-NIH-AIDS-2024 kept as "context" (not "supports") because it substantiates the concurrent-ART-continuation guidance but not the PLD dosing/chemotherapy content itself, which is drawn from the DRUG enti...

Used By

Algorithms

Disease

Indication